| Host: | HEK293 cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Formulation: | Lyophilised from 0.22 Mu m filtered solution in PBS (pH 7.4). |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: | < 0.1 EU/Mu g of the protein by LAL method. |
| Immunogen Region: | Cys24-Glu189 |
| Immunogen: | Recombinant Mouse IFN-alpha 6 Protein is produced by HEK293 cells system. The target protein is expressed with sequence (Cys24-Glu189) of Mouse IFN-alpha 6 (Accession #NP_996754.1) fused with His tag at the C-Terminus. |
| Immunogen Sequence: | CDLPQTHNLRNKKALTLLVQ MRRLSPLSCLKDRKDFGFPL EKVDAQQIQEAQAIPVLTEL TQQILTLFTSKDSSAAWNAT LLDSFCNDLHQQLNDLKACV MQEVGVQESPLTQEDSLLAV RTYFHRITVYLREKKHSPCA WEVVRAEVWRALSSSAKLLA RLSEDE |
| Background | Mature mouse IFNA6 consists of 166 aa and shares 60% aa identity with human IFNA6. The type I IFNs binds to the interferon alpha receptor (IFNAR) which consists of two subunits: IFNAR1 (alpha-subunit) and IFNAR2 (beta-subunit). Individual IFN alpha subtypes are known to display unique efficacies to viral protection, with IFNA6 displaying the superior efficacy controlling influenza virus infection and disease. Treatment with IFNA6 DNA 2 weeks post‐MCMV infection proved effective at inhibiting the development of chronic autoimmune myocarditis. IFNA6 is also able to reduce chronic cardiac inflammation. These findings suggest that immunomodulation of both antiviral and autoimmune responses by IFN DNA immunization may be an avenue for improved viral immunotherapy. |
Information sourced from Uniprot.org
